Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

NCT04669899 is registered in ClinicalTrials.gov with Jounce Therapeutics, Inc. as lead sponsor.

NCT NCT04669899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04669899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
Lead sponsor
Jounce Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 12, 2021
Completion date
November 28, 2023
Enrollment
190 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

cancer